Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The complaint claims Unicycive failed to inspect the vendor's facility and lacked reasonable basis to believe deficiencies were remedied, creating undisclosed risks of regulatory delays for oxylanthanum carbonate approval. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be eligible to join the case.